Screener
Taysha Gene Therapies, Inc. TSHA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of term loan | (1,470) | (1,530) |
| Interest income | 2,586 | 1,326 |
| Interest expense | (9) | (19) |
| Other income (expense) | (31) | 13 |
| Total other income (expense), net | 1,076 | (108) |
| Net loss | $(42,410) | $(21,529) |
| Net loss per common share, basic and diluted | $(0.12) | $(0.08) |
| Weighted average common shares outstanding, basic and diluted | 366,632,827 | 269,306,331 |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s net income?
- Taysha Gene Therapies, Inc. (TSHA) reported net income of -$42.41M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s net income changed year-over-year?
- Taysha Gene Therapies, Inc.'s net income decreased by 97.0% year-over-year, from -$21.53M to -$42.41M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s net income?
- Over 3 years (2021 to 2025), Taysha Gene Therapies, Inc.'s net income has grown at a -14.5% compound annual growth rate (CAGR), from -$174.52M to -$109M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Taysha Gene Therapies, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude